
Destiny Pharma publishes landmark XF-73 clinical data
Destiny Pharma, a UK-based clinical stage biotechnology company focused on the development of novel medicines to prevent life threatening infections, has published landmark XF-73 clinical data in the US peer reviewed journal Infection Control & Hospital Epidemiology. The paper was published by Dr. Julie Mangino… Read More







